Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Assets Average (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Assets Average data on record, last reported at $372.4 million in Q3 2025.

  • For Q3 2025, Assets Average rose 23.91% year-over-year to $372.4 million; the TTM value through Sep 2025 reached $372.4 million, up 23.91%, while the annual FY2024 figure was $249.9 million, 3.2% up from the prior year.
  • Assets Average reached $372.4 million in Q3 2025 per STOK's latest filing, down from $395.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $395.7 million in Q2 2025 and bottomed at $216.8 million in Q1 2024.
  • Average Assets Average over 4 years is $289.2 million, with a median of $275.9 million recorded in 2023.
  • Peak YoY movement for Assets Average: decreased 19.4% in 2024, then skyrocketed 56.49% in 2025.
  • A 4-year view of Assets Average shows it stood at $266.8 million in 2022, then fell by 12.27% to $234.1 million in 2023, then grew by 20.64% to $282.4 million in 2024, then skyrocketed by 31.85% to $372.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $372.4 million in Q3 2025, $395.7 million in Q2 2025, and $339.2 million in Q1 2025.